Barinthus Biotherapeutics plc
NASDAQ · us_market
No AI summary generated yet for this ticker.
Barinthus Biotherapeutics plc, together with its subsidiaries, engages in the research, development, and commercialization of immunotherapies and vaccines in the United States and the United Kingdom. The company develops VTP-1000, an antigen-specific immune tolerance candidate, which is in Phase I clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease; and VTP-300, an immunotherapy, which is in Phase II clinical trial for the treatment of chronic hepatitis B virus infection. It has a license agreement with Oxford University Innovation for the development and commercialization of products with thermo-responsive adjuvant scaffolds; and U.S. National Institutes of Health for the evaluation of synthetic and polymer-based vaccine technology to prevent infectious disease and treat cancer in animal models. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is based in Germantown, Maryland.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC are investigating the proposed merger of Barinthus Biotherapeutics plc and Clywedog...
Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) progressing towards closing which will result in a differentiated company focusing on metabolic and autoimmune pipeline assets with multiple important clinical development milestones in the 18 months after closingMultiple ascending dose part of the Phase 1 AVALON trial of VTP-1000 in celiac disease patients is progressing; data expected in the second half of 2026 GERMANTOWN, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Barinthus Biothe
Barinthus Biotherapeutics (NASDAQ:BRNS) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.30) by 53.33 percent. This is a 71.43 percent increase over losses of $(0.49) per
Qualcomm shares rose 10.6% in pre-market trading after reporting better-than-expected Q2 results. Other gainers include ABTS, AKAN, VSME, OSRH, AREB, VIAV, PI, INM, and MRAM.
Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) to create a differentiated company focusing on clinical metabolic and autoimmune pipeline assets and to build on the Company’s base of high caliber institutional investors, expected to complete in the second quarter of 2026Multiple ascending dose part of the Phase 1 AVALON trial of VTP-1000 in celiac disease patients is progressing; data expected in the second half of 2026 GERMANTOWN, Md., March 13, 2026 (GLOBE NEWSWIRE) -- Barint
Barinthus Biotherapeutics (NASDAQ:BRNS) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.40) by 32.5 percent. This is a 47.06 percent increase over losses of $(0.51) per
SEC Filing.
Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
VTP-1000, an antigen-specific immunotherapy to treat celiac disease, showed a dose-dependent pharmacological effect in the SAD portion of the trialVTP-1000 was well-tolerated with no treatment-related SAEs The MAD portion of the trial, which includes a gluten challenge, is ongoing GERMANTOWN, Md., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), an immunology and inflammation (“I&I”) company focused on developing immune tolerance
VTP-1000, an antigen-specific immunotherapy to treat celiac disease, showed a dose-dependent pharmacological effect in the SAD portion of the trialVTP-1000 was well-tolerated with no treatment-related SAEsThe MAD portion
HC Wainwright & Co. analyst Yi Chen maintains Barinthus Biotherapeutics (NASDAQ:BRNS) with a Buy and raises the price target from $3 to $4.
Single ascending dose data readout for VTP-1000 expected before the end of 2025Enrollment advancing in multiple ascending dose part of the AVALON trial; data expected in the second half of 2026Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) to strengthen and diversify the pipeline and broaden the Company’s base of high caliber institutional investors. GERMANTOWN, Md., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Compan
ChemDiv, a global provider of integrated drug discovery solutions, today announced that it will continue providing chemistry, computational, and clinical pharmacology support to Clywedog Therapeutics as the company enters into a definitive merger agreement with Barinthus Therapeutics (NASDAQ: BRNS). The combined entity will operate under the name Clywedog Therapeutics, Inc. and is expected to list on Nasdaq under the ticker CLYD upon closing. The merged portfolio will focus on advancing clinical
ChemDiv, a global provider of integrated drug discovery solutions, today announced that it will continue providing chemistry, computational, and clinical pharmacology support to Clywedog Therapeutics as the company
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| RenTech | quant | 151.0K | $85.92K | 0.00% | Added+5.5% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-04-30 | -0.28 | -0.14 | +50.00% |
| 2026-03-13 | -0.34 | -0.27 | +21.68% |
| 2025-11-07 | -0.39 | -0.24 | +38.23% |
| 2025-08-07 | -0.33 | -0.52 | -57.58% |
| 2025-05-07 | -0.36 | -0.49 | -36.11% |
| 2025-03-20 | -0.37 | -0.20 | +45.38% |
| 2024-11-06 | -0.44 | -0.21 | +52.63% |
| 2024-08-08 | -0.41 | -0.43 | -4.03% |
| 2024-05-13 | -0.61 | -0.40 | +34.43% |
| 2024-03-20 | -0.56 | -0.45 | +19.28% |
| 2023-11-09 | -0.55 | -0.37 | +32.11% |
| 2023-08-10 | -0.59 | -0.62 | -5.08% |
| 2023-05-12 | -0.58 | -0.48 | +17.24% |
| 2023-03-24 | -0.43 | -0.57 | -33.60% |
| 2022-11-10 | -0.52 | 0.22 | +143.13% |
| 2022-08-09 | -0.40 | 0.43 | +205.99% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| BRNS | +4.61% | +13.50% | -2.71% | -36.94% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | +1.64% | +18.14% | +0.73% | -49.63% |